# Dose-escalation Study of IMC-001 in Subject With Metastatic or Locally-advanced Solid Tumors

Source: https://onco.cc/trials/nct03644056/  
OnCo record `nct03644056` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of IMC-001 run by ImmuneOncia Therapeutics Inc., completed.

## Summary

Dose-escalation Study of IMC-001 in Subject With Metastatic or Locally-advanced Solid Tumors is a phase 1 interventional study registered as NCT03644056 by ImmuneOncia Therapeutics Inc., with 15 participants enrolled, started 2018-03-22. Conditions recorded: Solid Tumor, Metastasis and Locally Advanced. Interventions recorded: IMC-001.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03644056
- Phase: 1
- Setting: A Phase 1, Open-label, Multiple-ascending Dose Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of IMC-001 in Subjects With Metastatic or Locally-advanced Solid Tumors
- Sponsor: ImmuneOncia Therapeutics Inc.
- Enrolled: 15

## Sources

- ClinicalTrials.gov NCT03644056: https://clinicaltrials.gov/study/NCT03644056

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [IMC-001](https://onco.cc/drugs/imc-001/)
- companies: [ImmuneOncia Therapeutics](https://onco.cc/companies/immuneoncia-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct03644056.json